OCARINA 3NCT07667322
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Primary completion date changed from estimate of Feb 15, 2028 to Sep 1, 2026
- Minor Enrollment closed, study ongoing
- Site details revised at 12 of 12 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Adverse Events (AEs)
Timeframe: Up to 168 weeks
Secondary (3)
Ocrelizumab Serum Concentration at Specified Timepoints Following Single SC Administration
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADAs) to Ocrelizumab
Number of Participants With Treatment-emergent ADAs to rHuPH20
Arms and interventions
Ocrelizumab SCExperimental
Participants will receive single ascending doses of ocrelizumab SC, co-formulated with recombinant human hyaluronidase (rHuPH20) on Day 1 of the 24 week dose-escalation phase. Participants who opt to continue treatment in the dose continuation phase will receive ocrelizumab SC at a dose determined in the dose escalation phase, every 24 weeks (Q24W) for 144 weeks.
Drugs: Ocrelizumab Co-formulated With rHuPH20
Sites
12 sites in 4 countries
United States 6, Brazil 2, Mexico 2, United Kingdom 2